<DOC>
	<DOC>NCT01983111</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of buprenorphine transdermal system to tramadol/acetaminophen.</brief_summary>
	<brief_title>Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Korean men and women aged 20 years or more Presence of pain associated with a spinal disease and lumbar fusion at 12 spinal segments (12 level lumbar fusion surgery) Moderate to severe pain of the NRS pain score â‰¥ 4 at Visit 1 (14~90 days after surgery, Baseline) (Amended 21Nov2013) Consent to participate in the study and voluntary signature on the informed consent form Women of childbearing potential, except for the following cases: A partner who is vasectomized or otherwise surgically sterile. Use of 2 contraception methods. Two methods include the combination of doublebarrier contraception or barrier contraception and hormone contraception, and appropriate barrier methods are as follows: Diaphragm (female contraceptive device), condom, intrauterine (copper or hormone), sponge or spermicide. Hormonal contraceptives include all commercially available products containing estrogen and/or progesterone. Pregnant or breastfeeding women. Pregnant woman is defined as a woman after fertilization to late pregnancy with a positive result from the urine pregnancy test. History of hypersensitivity to buprenorphine, tramadol, APAP or excipients, and celecoxib Medical history of asthma, acute rhinitis, nasal polyp, vascular edema urticaria or allergic reaction to aspirin or other nonsteroidal antiinflammatory drugs(NSAIDs, COX2) Hypersensitivity or intolerance to Domperidone Risk of gastrointestinal irritation such as gastrointestinal bleeding, mechanical ileus or perforation Genetic problem such as galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption Severely impaired respiratory function or respiratory depression Current use of monoamine oxidase(MAO) inhibitors or the medication history within 2 weeks prior to study participation Convulsive disorder, head injury, shock, decreased level of consciousness of uncertain origin, intracranial lesion or increased intracranial pressure or severe hepatic impairment Biliary tract disorder Presence or suspected drug abuse history Medical history of opioid or drug dependence Current use of other CNS inhibitors or muscle relaxants that may result in dyspnea, hypotension, severe sedation or coma when used with the investigational product, opioid analgesics Use of strong opioids, buprenorphine or tramadol/APAP within 1 week prior to study participation (however, study participation is allowed for PRN prescription of PCA and strong opioids) Any condition representing a contraindication of application of buprenorphine, tramadol/APAP or celecoxib Major pain not attributable to a spinal disease Anticancer therapy that may affect pain assessment Clinically significant cardiovascular or renal dysfunction Postoperative complications Symptoms of acute pain after lumbar fusion or characteristic analgesic features showing rapidly changing needs for analgesics Current use of other investigational product at enrollment or within 30 days after administration of other investigational product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>